Table 1.

Baseline characteristics of patients on dialysis, kidney transplant recipients, and controls without evidence of kidney failure

CharacteristicsDialysis (n=32)KTR (n=28)Control (n=78)
General
 Age (yr), median (IQR)83 (80–85)66 (61–81)84 (80–87)
 Male sex, %697129
 BMI (kg/m2)a2627n.d.
 Diabetes, %2811n.d.
Vaccine
 BioNTech/Pfizer, n (%)32 (100)23 (82)78 (100)
 Moderna, n (%)05 (18)0
 Sample taken after first vaccination (d), median (IQR)20 (19–21)20 (19–20)19 (17–19)
 Sample taken after second vaccination (d), median (IQR)14 (13–15)14 (14–15)17
Dialysis
 Treatment duration (yr), median (IQR)3 (2–6)
 PD, n1
 HD, n31
 History of previous transplantation, n (%)2 (6)
 Responder to hepatitis B vaccination, n (%)12 (38)
 Nonresponder to hepatitis B vaccination, n (%)13 (40)
 No hepatitis B vaccination/not determined, n (%)7 (22)
 Immunosuppressive treatment, n (%)5 (16)
Transplantation
 Years after transplantation (yr), median (IQR)10 (3–12)
 History of previous transplantation, n2
 Baseline eGFR (ml/min per 1.73 m2), mean±SD46±20
 Triple immunosuppressive treatment, n (%)22 (79)
 Dual immunosuppressive treatment, n (%)6 (21)
 Basiliximab, n (%)16 (57)
 Tacrolimus, n (%)25 (89)
 Ciclosporin, n (%)3 (11)
 Mycophenolate mofetil, n (%)22 (79)
 Azathioprine, n (%)1 (4)
 Prednisolone, n (%)27 (96)
  • KTR, kidney transplant recipient; IQR, interquartile range; BMI, body mass index; n.d., not determined; PD, peritoneal dialysis; HD, hemodialysis.

  • a Values represent mean values.